Home › Glioma › Texas › Houston

Glioma clinical trials in Houston, TX

24 studies for Glioma are looking for participants at sites in and around Houston (within about 30 miles). Open a study to see who can join and how to contact the study team.

Recruiting for a study here? Feature it at the top of this page — $99 for 30 days →

Study of Silevertinib With Temozolomide for the Treatment of Newly Diagnosed GBM With Unmethylated MGMT and EGFRvIII

RecruitingPhase 2

UT MD Anderson Cancer Center, Houston

Ages 18 and older · All sexes · Updated Nov 12, 2026 · NCT07326566

A Phase I Clinical Study of YN003 in the Treatment of Glioma

RecruitingPhase 1

The University of Texas MD Anderson Cancer Center, Houston

Ages 18 to 70 · All sexes · Updated Nov 10, 2026 · NCT07929909

Window-of-Opportunity Trial of Ulixertinib for MAPK-Activated Gliomas

RecruitingEarly phase 1

M D Anderson Cancer Center, Houston

Ages 18 and older · All sexes · Updated Nov 2, 2026 · NCT05804227

ACT001 for the Treatment of Diffuse Intrinsic Pontine Gliomas and H3K27-altered High Grade Gliomas

RecruitingPhase 2

Texas Children's Hospital, Houston

12 Months – 39 Years · All sexes · Updated Oct 23, 2026 · NCT06838676

Safety and Tolerability of TNG456 Alone and in Combination With Abemaciclib in Patients With Solid Tumors With MTAP Loss

RecruitingPhase 1/2

MD Anderson Cancer Center, Houston

Ages 18 and older · All sexes · Updated Oct 21, 2026 · NCT06810544

SIGMA (Safusidenib in IDH1 Mutant Glioma Maintenance)

RecruitingPhase 3

MD Anderson Cancer Center, Houston

Ages 18 and older · All sexes · Updated Oct 19, 2026 · NCT05303519

Engineered HSV-1 M032 for the Treatment of Children and Adults With Newly Diagnosed Diffuse Midline Glioma After Standard of Care Radiation

RecruitingPhase 1

The University of Texas M. D. Anderson Cancer Center, Houston

36 Months · All sexes · Updated Oct 9, 2026 · NCT07076498

Study of AZD9574 as Monotherapy and in Combination With Anti-cancer Agents in Participants With Advanced Solid Malignancies

RecruitingPhase 1/2

Research Site, Houston

Ages 18 to 130 · All sexes · Updated Oct 5, 2026 · NCT05417594

A Study of Repotrectinib in Pediatric and Young Adult Subjects Harboring ALK, ROS1, OR NTRK1-3 Alterations

RecruitingPhase 1/2

Baylor College of Medicine, Houston

Up to age 25 · All sexes · Updated Sep 25, 2026 · NCT04094610

MSC-DNX-2401 in Treating Patients With Recurrent High-Grade Glioma

RecruitingPhase 1

M D Anderson Cancer Center, Houston

Ages 18 and older · All sexes · Updated Sep 25, 2026 · NCT03896568

MRE Scan for the Assessment of Differences in Tissue Stiffness Between Radiation Necrosis and Recurrent Glioma in Patients With Previously Treated Gliomas

Recruiting

M D Anderson Cancer Center, Houston

Ages 18 and older · All sexes · Updated Sep 14, 2026 · NCT04373720

Serial Advanced Magnetic Resonance Imaging Scan for Guidance of Personalized Adaptive Radiotherapy for High Grade Glioma

RecruitingObservational study

M D Anderson Cancer Center, Houston

Ages 18 and older · All sexes · Updated Sep 14, 2026 · NCT04771806

Targeted Pediatric High-Grade Glioma Therapy

RecruitingObservational study

Texas Children's Hospital, Houston

12 Months – 39 Years · All sexes · Updated Sep 8, 2026 · NCT05839379

HSV G207 in Children With Recurrent or Refractory Cerebellar Brain Tumors

RecruitingPhase 1

MD Anderson Cancer Center, Houston

36 Months – 22 Years · All sexes · Updated Sep 4, 2026 · NCT03911388

Study of Olutasidenib and Temozolomide in HGG

RecruitingPhase 2

Texas Children's Hospital, Houston

Ages 12 to 39 · All sexes · Updated Sep 1, 2026 · NCT06161974

PEP-CMV Vaccine Targeting CMV Antigen to Treat Newly Diagnosed Pediatric HGG and DIPG and Recurrent Medulloblastoma

RecruitingPhase 2

Texas Children's Hospital, Houston

Ages 3 to 39 · All sexes · Updated Aug 24, 2026 · NCT05096481

Molecular Testing for the MD Anderson Cancer Center Personalized Cancer Therapy Program

RecruitingObservational study

M D Anderson Cancer Center, Houston

All ages · All sexes · Updated Aug 21, 2026 · NCT01772771

Study of 203Pb-RMX-VH-PIB Dosimetry and Biodistribution in Patients With Glioblastoma Multiform (GBM) and Pancreatic Ductal Adenocarcinoma (PDAC)

RecruitingPhase 1

Excel Diagnostics & Nuclear Oncology Center, Houston

Ages 18 and older · All sexes · Updated Aug 7, 2026 · NCT07733674

C7R-GD2.CAR T Cells for Patients With GD2-expressing Brain Tumors (GAIL-B)

RecruitingPhase 1

Texas Children's Hospital, Houston

12 Months – 25 Years · All sexes · Updated Aug 3, 2026 · NCT04099797

A Study to Assess the Efficacy and Safety of FORE8394 in Participants With Cancer Harboring BRAF Alterations

RecruitingPhase 2

University of Texas MD Anderson Cancer Center, Houston

Ages 8 and older · All sexes · Updated Jul 27, 2026 · NCT05503797

Lorlatinib for Newly-Diagnosed High-Grade Glioma With ROS or ALK Fusion

RecruitingEarly phase 1Healthy volunteers welcome

Texas Children's Hospital, Houston

Ages 1 to 21 · All sexes · Updated Jun 29, 2026 · NCT06333899

Study of Ribociclib and Everolimus in HGG and DIPG or Ribociclib and Temozolomide in DHG, H3G34-mutant

RecruitingPhase 2

Texas Children's Hospital, Houston

12 Months – 39 Years · All sexes · Updated May 29, 2026 · NCT05843253

A Study to Investigate the Safety and Efficacy of NST-628 Oral Tablets in Subjects With Solid Tumors

RecruitingPhase 1

MD Anderson Cancer Center, Houston

Ages 18 and older · All sexes · Updated Apr 20, 2026 · NCT06326411

A Pilot Study of Larotrectinib for Newly-Diagnosed High-Grade Glioma With NTRK Fusion

RecruitingEarly phase 1

Texas Children's Hospital, Houston

Up to age 21 · All sexes · Updated Mar 18, 2026 · NCT04655404

Glioma trials in other cities

Other studies in Houston

From ClinicalTrials.gov, data retrieved Nov 15, 2026. Each study sets its own eligibility; the study team decides who can join.